Anti-TL1A x IL-23 therapy(Generate Biomedicines)

N/A

Report date: 2025/04/30 14:19:37

Base Information

Drug NameAnti-TL1A x IL-23 therapy(Generate Biomedicines)

Drug Alias NameBispecific antibody for ulcerative colitis (Generate Biomedicines)

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-Tumor necrosis factor superfamily member 15Interleukin 23 Receptor inhibitors

TargetsTumor necrosis factor superfamily member 15Interleukin 23 Receptor

Therapy Area/IndicationsColitis, Ulcerative

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesGenerate Biomedicines Inc

China Registration ClassN/A

Develop Information

Active CompaniesGenerate Biomedicines Inc

Inactive CompaniesN/A

Active IndicationsColitis, Ulcerative

Inactive IndicationsN/A

Other Information

ATC CodeN/A